AVONEX

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

INTERFERON BETA 1A 30 MCG/VIAL

MAH:

MEDISON PHARMA LTD

ATC_code:

L03AB07

pharmaceutical_form:

POWDER FOR SOLUTION FOR INJECTION

administration_route:

I.M

manufactured_by:

BIOGEN IDEC LTD, UK

therapeutic_group:

INTERFERON BETA-1A

therapeutic_indication:

Avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. Avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of MRI abnormalities characteristic of MS and if they are determined to be at high risk of developing clinically definite multiple sclerosis. Safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

authorization_date:

2011-11-01